DNB Carnegie acted as global coordinator and sole bookrunner in the fully guaranteed rights issue of approximately SEK 36.6 million in Iconovo.
Iconovo’s innovative and patent-protected inhalators enable the development of new effective and user-friendly pharmaceuticals for an array of diseases.